Histologically confirmed newly diagnosed Stage I-II breast cancer Women of reproductive potential must be non-pregnant and non-nursing and must agree to employ an effective barrier method of birth control throughout the study and for up to 6 months following treatment Women of child-bearing potential must have a negative pregnancy test within 7 days of initiating study Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Absolute neutrophil count greater than or equal to 1,500/mcl Platelet count equal to or greater than 150,000/mcl Hemoglobin > 11gm/dl Alkaline phosphatase equal or less than 1.5 times the upper limit of normal (ULN) Total bilirubin equal to or less than 1.5 times the ULN Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) no greater than 1.5 times the ULN Creatinine less than 1.5 times the ULN Able to give informed consent All included patients must have normal cardiac function as defined by an ejection fraction of > 50% by echocardiogram Able to return for treatment and follow-up on the specified days